Trials / Completed
CompletedNCT04198571
Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalised for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated With Zinforo (REGISTERED) (Ceftaroline Fosamil) in a Usual Care Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 317 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
MULTINATIONAL Retrospective Chart Review Study to Assess the Characteristics, Treatment Outcomes and Resource Use Among Adult Patients Hospitalized for Community-Acquired Pneumonia (CAP) or Complicated Skin and Soft Tissue Infections (cSSTI) Treated with Zinforo® (ceftaroline fosamil) in a Usual Care Setting
Detailed description
The overall study aim is to provide real world evidence (RWE) on the characteristics, clinical management, treatment outcomes and healthcare resource use of adult patients aged 18 years and older admitted to the hospital for CAP or cSSTI who received Zinforo® in a usual care setting in Europe and Latin America on or before 31-May-2019.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zinforo (ceftaroline fosamil) | IV Solution |
Timeline
- Start date
- 2020-05-17
- Primary completion
- 2021-07-23
- Completion
- 2021-08-30
- First posted
- 2019-12-13
- Last updated
- 2024-03-26
- Results posted
- 2024-03-26
Locations
26 sites across 7 countries: Brazil, Colombia, France, Greece, Italy, Russia, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04198571. Inclusion in this directory is not an endorsement.